{"nctId":"NCT02158546","briefTitle":"A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study","startDateStruct":{"date":"2014-05"},"conditions":["Major Depressive Disorder"],"count":447,"armGroups":[{"label":"ALKS 5461","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 5461"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"ALKS 5461","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a Body Mass Index (BMI) of 18.0 to 40.0 kg/m2, inclusive\n* Agree to use an acceptable method of contraception for the duration of the study\n* Have a Major Depressive Disorder (MDD) primary diagnosis\n* Have no more than 2 inadequate responses to antidepressant therapy (ADT) in the current Major Depressive Episode (MDE)\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Have a current primary Axis-I disorder other than MDD\n* Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days\n* Have received electroconvulsive therapy treatment within the last 2 years or received more than one course of electroconvulsive treatment during lifetime\n* Have attempted suicide within the past 2 years\n* Have a positive test for drugs of abuse\n* Are pregnant, planning to become pregnant, or breastfeeding\n* Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone)\n* Have had a significant blood loss or blood donation within 60 days\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to End of Treatment (Week 6) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","description":"The MADRS-10 scale is a clinician-administered questionnaire comprised of 10 items used to measure the severity of MDD symptoms. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms). Individual questionnaire items include: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"0.67"},{"groupId":"OG001","value":"-4.6","spread":"0.66"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Who Exhibited Treatment Response (MADRS-10)","description":"The proportion of subjects demonstrating MADRS-10 treatment response, defined as a ≥ 50% reduction in MADRS-10 score from baseline to the end of the efficacy period (week 6).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission Rate","description":"The proportion of subjects achieving remission, defined as a MADRS-10 score of ≤ 10 at the end of the efficacy period.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events (AEs)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":147},"commonTop":["Nausea","Headache","Dry mouth","Fatigue","Upper respiratory tract infection"]}}}